You are here: Industry Insights > T-cell therapies

News List

Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer pharmaceutical-business-review
January 17, 2020
Astellas Pharma has signed a deal worth up to $897.5m with Adaptimmune Therapeutics to co-develop and co-commercialise stem-cell derived allogeneic CAR-T and TCR T-cell therapies for cancer.
Eureka Therapeutics Announces Data Presentations Validating Its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting firstwordpharma
December 02, 2018
Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, announced today that five abstracts, including four oral pr
Eureka Therapeutics Announces Data Presentations Validating Its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting firstwordpharma
December 02, 2018
Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, announced today that five abstracts, including four oral pr
CRISPR and Massachusetts General Hospital partner to develop T-cell therapies pharmaceutical-technology
August 25, 2017
CRISPR Therapeutics has entered a new research collaboration and licence option agreement with Massachusetts General Hospital Cancer Centre (MGHCC) to develop new T-cell therapies for cancer.